Characteristics of participants by sex and stem cell source in HCT
| . | Men . | Women . | ||||||
|---|---|---|---|---|---|---|---|---|
| Stem cell source, no. patients . | P† . | Stem cell source, no. patients . | P† . | |||||
| Total, N = 152 . | Autologous, n = 82 . | Allogeneic,* n = 70 . | Total, N = 125 . | Autologous, n = 64 . | Allogeneic, n = 61 . | |||
| No. of participants (% of total) | ||||||||
| Pre-HCT‡ | 143 (94.1) | 76 (92.7) | 67 (95.7) | – | 113 (90.4) | 57 (89.1) | 56 (91.8) | – |
| 6 mo | 66 (43.4) | 42 (51.2) | 24 (33.3) | 72 (57.6) | 39 (60.9) | 33 (54.1) | ||
| 1 y | 59 (38.8) | 37 (45.1) | 22 (30.6) | 71 (56.8) | 36 (56.2) | 35 (57.4) | ||
| 2 y | 58 (38.2) | 40 (48.8) | 18 (25.0) | 65 (52.0) | 31 (48.4) | 34 (55.7) | ||
| 3 y | 69 (45.4) | 44 (53.6) | 25 (34.7) | 68 (54.4) | 33 (51.6) | 35 (57.4) | ||
| Median age at referent HCT,§ y (range) | 49.5 (18-74) | 55 (18-73) | 44 (19-74) | <.001 | 46 (19-70) | 48 (19-70) | 45 (19-63) | .23 |
| Race/ethnicity, n (%) | ||||||||
| Non-Hispanic whites | 98 (64.5) | 57 (69.5) | 41 (58.6) | .07 | 84 (67.2) | 43 (67.2) | 41 (67.2) | .50 |
| Hispanics | 29 (19.1) | 12 (14.6) | 17 (24.3) | 21 (16.8) | 10 (15.6) | 11 (18.0) | ||
| Blacks | 8 (5.3) | 7 (8.5) | 1 (1.4) | 8 (6.4) | 6 (9.4) | 2 (3.3) | ||
| Asians | 15 (9.9) | 5 (6.1) | 10 (14.3) | 9 (7.2) | 3 (4.7) | 6 (9.8) | ||
| Other | 2 (1.3) | 1 (1.2) | 1 (1.4) | 3 (2.4) | 2 (3.1) | 1 (1.6) | ||
| Married, at pre-HCT, N (%) | 107 (70.4) | 63 (76.8) | 44 (62.9) | .06 | 75 (60.0) | 37 (57.8) | 38 (62.3) | .61 |
| Education, highest attainedat pre-HCT, n (%) | ||||||||
| High school or less | 37 (24.3) | 20 (24.4) | 17 (24.3) | .75 | 23 (18.4) | 13 (20.3) | 10 (16.4) | .70 |
| Some college | 42 (27.6) | 21 (25.6) | 21 (30.0) | 48 (38.4) | 23 (35.9) | 25 (41.0) | ||
| Bachelor’s degree or higher | 72 (47.4) | 40 (48.8) | 32 (45.7) | 53 (42.4) | 27 (42.2) | 26 (42.6) | ||
| Unknown | 1 (0.7) | 1 (1.2) | 0 | 1 (0.8) | 1 (1.6) | 0 | ||
| Annual household income at pre-HCT, n (%) | ||||||||
| <$50 000 | 52 (34.2) | 27 (32.9) | 25 (35.7) | .80 | 38 (30.4) | 23 (35.9) | 15 (24.6) | .38 |
| $50 000-$74 999 | 47 (30.9) | 25 (30.5) | 22 (31.4) | 37 (29.6) | 17 (26.6) | 20 (32.8) | ||
| ≥$75 000 | 52 (34.2) | 29 (35.4) | 23 (32.9) | 49 (39.2) | 23 (35.9) | 26 (42.6) | ||
| Unknown | 1 (0.7) | 1 (1.2) | 0 | 1 (0.8) | 1 (1.6) | 0 | ||
| BMI (kg/m2) at pre-HCT, mean ± SD | 27.8 ± 4.6 | 28.3 ± 4.7 | 27.1 ± 4.4 | .092 | 27.7 ± 7.1 | 27.7 ± 7.4 | 27.7 ± 6.8 | .97 |
| Primary diagnosis, n (%) | ||||||||
| Acute leukemia | 54 (35.5) | 11 (13.4) | 43 (61.4) | <.001 | 47 (37.6) | 13 (20.3) | 34 (55.7) | <.001 |
| Lymphoma | 55 (36.2) | 42 (51.2) | 13 (18.6) | 46 (36.8) | 37 (57.8) | 9 (14.8) | ||
| MM | 34 (22.4) | 29 (35.4) | 5 (7.1) | 15 (12.0) | 14 (21.9) | 1 (1.6) | ||
| Other|| | 9 (5.9) | 0 | 9 (12.9) | 17 (13.6) | 0 | 17 (27.9) | ||
| High risk of relapse at HCT, n (%) | 88 (57.9) | 56 (68.3) | 32 (45.7) | .005 | 56 (44.8) | 34 (53.1) | 22 (36.1) | .055 |
| Disease in remission at HCT, n (%) | 55 (36.2) | 26 (31.7) | 29 (41.4) | .31 | 47 (37.6) | 28 (43.8) | 19 (31.2) | .16 |
| Chronic GVHD,¶n (%) | ||||||||
| 6 mo | – | NA | 9 (37.5)# | – | – | NA | 10 (30.3)# | – |
| 1 y | – | NA | 9 (40.9) | – | NA | 19 (54.3) | ||
| 2 y | – | NA | 13 (72.2) | – | NA | 17 (50.0) | ||
| 3 y | – | NA | 17 (68.0) | – | NA | 16 (45.7) | ||
| No. of HCT (%) | ||||||||
| 1 | 119 (78.3) | 70 (85.4) | 49 (70.0) | .02 | 104 (83.2) | 57 (89.1) | 47 (77.0) | .072 |
| ≥2 | 33 (21.7) | 12 (14.6) | 21 (30.0) | 21 (16.8) | 7 (10.9) | 14 (23.0) | ||
| TBI, n (%) | 67 (44.1) | 28 (34.2) | 39 (55.7) | .008 | 58 (46.4) | 28 (43.8) | 30 (49.2) | .54 |
| Median dose (range) among irradiated, in cGy | 1200 (200-1350) | 1200 (1200-1200) | 1320 (200-1350) | <.001 | 1200 (200-1320) | 1200 (1200-1200) | 1320 (200-1320) | .0023 |
| Medication at pre-HCT, n (%) | ||||||||
| Sexually protective/enhancing | 6 (4.0) | 3 (3.7) | 3 (4.3) | .84 | 37 (29.6) | 23 (35.9) | 14 (23.0) | .11 |
| Other types of medications | 53 (34.9) | 36 (43.9) | 17 (24.3) | .01 | 53 (42.4) | 32 (50.0) | 21 (34.4) | .078 |
| . | Men . | Women . | ||||||
|---|---|---|---|---|---|---|---|---|
| Stem cell source, no. patients . | P† . | Stem cell source, no. patients . | P† . | |||||
| Total, N = 152 . | Autologous, n = 82 . | Allogeneic,* n = 70 . | Total, N = 125 . | Autologous, n = 64 . | Allogeneic, n = 61 . | |||
| No. of participants (% of total) | ||||||||
| Pre-HCT‡ | 143 (94.1) | 76 (92.7) | 67 (95.7) | – | 113 (90.4) | 57 (89.1) | 56 (91.8) | – |
| 6 mo | 66 (43.4) | 42 (51.2) | 24 (33.3) | 72 (57.6) | 39 (60.9) | 33 (54.1) | ||
| 1 y | 59 (38.8) | 37 (45.1) | 22 (30.6) | 71 (56.8) | 36 (56.2) | 35 (57.4) | ||
| 2 y | 58 (38.2) | 40 (48.8) | 18 (25.0) | 65 (52.0) | 31 (48.4) | 34 (55.7) | ||
| 3 y | 69 (45.4) | 44 (53.6) | 25 (34.7) | 68 (54.4) | 33 (51.6) | 35 (57.4) | ||
| Median age at referent HCT,§ y (range) | 49.5 (18-74) | 55 (18-73) | 44 (19-74) | <.001 | 46 (19-70) | 48 (19-70) | 45 (19-63) | .23 |
| Race/ethnicity, n (%) | ||||||||
| Non-Hispanic whites | 98 (64.5) | 57 (69.5) | 41 (58.6) | .07 | 84 (67.2) | 43 (67.2) | 41 (67.2) | .50 |
| Hispanics | 29 (19.1) | 12 (14.6) | 17 (24.3) | 21 (16.8) | 10 (15.6) | 11 (18.0) | ||
| Blacks | 8 (5.3) | 7 (8.5) | 1 (1.4) | 8 (6.4) | 6 (9.4) | 2 (3.3) | ||
| Asians | 15 (9.9) | 5 (6.1) | 10 (14.3) | 9 (7.2) | 3 (4.7) | 6 (9.8) | ||
| Other | 2 (1.3) | 1 (1.2) | 1 (1.4) | 3 (2.4) | 2 (3.1) | 1 (1.6) | ||
| Married, at pre-HCT, N (%) | 107 (70.4) | 63 (76.8) | 44 (62.9) | .06 | 75 (60.0) | 37 (57.8) | 38 (62.3) | .61 |
| Education, highest attainedat pre-HCT, n (%) | ||||||||
| High school or less | 37 (24.3) | 20 (24.4) | 17 (24.3) | .75 | 23 (18.4) | 13 (20.3) | 10 (16.4) | .70 |
| Some college | 42 (27.6) | 21 (25.6) | 21 (30.0) | 48 (38.4) | 23 (35.9) | 25 (41.0) | ||
| Bachelor’s degree or higher | 72 (47.4) | 40 (48.8) | 32 (45.7) | 53 (42.4) | 27 (42.2) | 26 (42.6) | ||
| Unknown | 1 (0.7) | 1 (1.2) | 0 | 1 (0.8) | 1 (1.6) | 0 | ||
| Annual household income at pre-HCT, n (%) | ||||||||
| <$50 000 | 52 (34.2) | 27 (32.9) | 25 (35.7) | .80 | 38 (30.4) | 23 (35.9) | 15 (24.6) | .38 |
| $50 000-$74 999 | 47 (30.9) | 25 (30.5) | 22 (31.4) | 37 (29.6) | 17 (26.6) | 20 (32.8) | ||
| ≥$75 000 | 52 (34.2) | 29 (35.4) | 23 (32.9) | 49 (39.2) | 23 (35.9) | 26 (42.6) | ||
| Unknown | 1 (0.7) | 1 (1.2) | 0 | 1 (0.8) | 1 (1.6) | 0 | ||
| BMI (kg/m2) at pre-HCT, mean ± SD | 27.8 ± 4.6 | 28.3 ± 4.7 | 27.1 ± 4.4 | .092 | 27.7 ± 7.1 | 27.7 ± 7.4 | 27.7 ± 6.8 | .97 |
| Primary diagnosis, n (%) | ||||||||
| Acute leukemia | 54 (35.5) | 11 (13.4) | 43 (61.4) | <.001 | 47 (37.6) | 13 (20.3) | 34 (55.7) | <.001 |
| Lymphoma | 55 (36.2) | 42 (51.2) | 13 (18.6) | 46 (36.8) | 37 (57.8) | 9 (14.8) | ||
| MM | 34 (22.4) | 29 (35.4) | 5 (7.1) | 15 (12.0) | 14 (21.9) | 1 (1.6) | ||
| Other|| | 9 (5.9) | 0 | 9 (12.9) | 17 (13.6) | 0 | 17 (27.9) | ||
| High risk of relapse at HCT, n (%) | 88 (57.9) | 56 (68.3) | 32 (45.7) | .005 | 56 (44.8) | 34 (53.1) | 22 (36.1) | .055 |
| Disease in remission at HCT, n (%) | 55 (36.2) | 26 (31.7) | 29 (41.4) | .31 | 47 (37.6) | 28 (43.8) | 19 (31.2) | .16 |
| Chronic GVHD,¶n (%) | ||||||||
| 6 mo | – | NA | 9 (37.5)# | – | – | NA | 10 (30.3)# | – |
| 1 y | – | NA | 9 (40.9) | – | NA | 19 (54.3) | ||
| 2 y | – | NA | 13 (72.2) | – | NA | 17 (50.0) | ||
| 3 y | – | NA | 17 (68.0) | – | NA | 16 (45.7) | ||
| No. of HCT (%) | ||||||||
| 1 | 119 (78.3) | 70 (85.4) | 49 (70.0) | .02 | 104 (83.2) | 57 (89.1) | 47 (77.0) | .072 |
| ≥2 | 33 (21.7) | 12 (14.6) | 21 (30.0) | 21 (16.8) | 7 (10.9) | 14 (23.0) | ||
| TBI, n (%) | 67 (44.1) | 28 (34.2) | 39 (55.7) | .008 | 58 (46.4) | 28 (43.8) | 30 (49.2) | .54 |
| Median dose (range) among irradiated, in cGy | 1200 (200-1350) | 1200 (1200-1200) | 1320 (200-1350) | <.001 | 1200 (200-1320) | 1200 (1200-1200) | 1320 (200-1320) | .0023 |
| Medication at pre-HCT, n (%) | ||||||||
| Sexually protective/enhancing | 6 (4.0) | 3 (3.7) | 3 (4.3) | .84 | 37 (29.6) | 23 (35.9) | 14 (23.0) | .11 |
| Other types of medications | 53 (34.9) | 36 (43.9) | 17 (24.3) | .01 | 53 (42.4) | 32 (50.0) | 21 (34.4) | .078 |
NA, not applicable.
Patients who received any allogeneic HCT were classified as allogeneic recipients.
Comparison by stem cell source.
Nine male and 12 female patients did not respond at pre-HCT but responded at least once at subsequent follow-up.
The referent HCT for patients who underwent multiple HCT is the specific transplantation that prompted his/her study enrollment.
CML (n = 16); SAA (n = 6); CLL (n = 3); other leukemia (1).
Self-reported.
Percent of participants at the assessment time point.